UP TO $120M PER PROGRAM
Immunocore signs Astrazeneca to latest T-cell collaboration
By Nuala Moran
Tuesday, January 7, 2014
LONDON – Another pharma has fallen for the attractions of Immunocore Ltd.’s T-cell receptors, with Astrazeneca plc signing a multiple-target deal with a price tag of $320 million per program.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.